Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Imatinib and Nilotinib in Ph+ CML-CP
NCT02272777Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of nilotinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Novartis. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 31 months. Started Jul 2014; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02272777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02272777.